LncRNA SNHG10 increases the methylation of miR-218 gene to promote glucose uptake and cell proliferation in osteosarcoma
- PDF / 1,420,211 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 0 Downloads / 151 Views
(2020) 15:353
RESEARCH ARTICLE
Open Access
LncRNA SNHG10 increases the methylation of miR-218 gene to promote glucose uptake and cell proliferation in osteosarcoma Pan He, Yongqiang Xu* and Zhijun Wang
Abstract Background: This study aimed to investigate the roles of lncRNA SNHG10 (SNHG10) and miR-218 in osteosarcoma (OS). Methods: Paired OS and non-tumor tissues were collected from 58 OS patients. The expression of SNHG10 and miR-218 in tissue samples were determined by RT-qPCR. The interaction between SNHG10 and miR-218 was evaluated by overexpression experiment. Methylation-specific PCR was performed to assess the methylation status of miR-218. Glucose uptake in OS cells was analyzed by glucose uptake assay. Cell proliferation was detected by cell proliferation assay. Results: SNHG10 was upregulated in OS, while miR-218 was downregulated in OS. The expression of SNHG10 and miR-218 were inversely correlated. In OS cells, high glucose induced the upregulation of SNHG10 and downregulation of miR-218. In OS cells, SNHG10 positively, and miR-218 negatively regulated glucose uptake. Overexpression of SNHG10 increased miR-218 gene methylation and decreased the expression of miR-218. In addition, overexpression of SNHG10 also suppressed the inhibitory effects of overexpression of miR-218 on cell proliferation. Conclusions: SNHG10 increases the methylation of miR-218 gene to promote glucose uptake and cell proliferation in OS. Keywords: SNHG10, miR-218, Osteosarcoma, Glucose, Methylation
Background As a type of malignancy that causes the production of immature bone, osteosarcoma mainly affects patients younger than 25 years old [1, 2]. In the USA, OS affects 800 to 900 new cases every year [2]. Although a slight higher incidence of OS was observed in China, it only affects 4 out of 1 million people annually [3]. With * Correspondence: [email protected] Department of Traumatic and Osteopathy, Hunan Provincial People’s Hospital, No. 61 Jiefang West Road, Changsha 410005, Hunan Province, China
appropriate surgical operations combined with pre- and post-operative chemotherapy, the overall survival rate of non-metastatic OS patients can reach 77% [4]. However, distant metastasis to other sites of the human body, such as brain and lung, is common in OS [5, 6]. Currently, effective treatments for metastatic OS remain lacking, leading to high mortality rate [7]. Therefore, novel therapeutic approaches are needed. Targeted therapy, which aims to suppress human diseases mainly by regulating disease-related gene expression, is emerging novel therapeutic approach for cancer
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the arti
Data Loading...
